1. Home
  2. CTW vs BMEA Comparison

CTW vs BMEA Comparison

Compare CTW & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CTW Cayman Class A Ordinary Shares

CTW

CTW Cayman Class A Ordinary Shares

HOLD

Current Price

$2.34

Market Cap

171.0M

Sector

Technology

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.74

Market Cap

140.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTW
BMEA
Founded
2013
2017
Country
Japan
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
171.0M
140.3M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
CTW
BMEA
Price
$2.34
$1.74
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$9.83
AVG Volume (30 Days)
23.4K
2.0M
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.19
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$22.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$0.87
52 Week High
$3.14
$2.99

Technical Indicators

Market Signals
Indicator
CTW
BMEA
Relative Strength Index (RSI) 36.18 56.35
Support Level $2.00 $1.17
Resistance Level $2.58 $2.00
Average True Range (ATR) 0.29 0.17
MACD -0.05 0.01
Stochastic Oscillator 0.76 54.91

Price Performance

Historical Comparison
CTW
BMEA

About CTW CTW Cayman Class A Ordinary Shares

CTW operates as a gaming platform company providing instant access to free-to-play, browser-based games inspired by popular Japanese animation, including "So I'm a Spider, So What? Ruler of the Labyrinth, Arifureta: From Commonplace to World's Strongest - Rebellion Soul", and "Queen's Blade Limit Break". CTW delivers these games through its flagship HTML5 platform, G123.jp.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: